{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T04:23:36Z","timestamp":1729657416385,"version":"3.28.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,22]]},"DOI":"10.7759\/cureus.72140","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T17:24:42Z","timestamp":1729617882000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond the Obvious: The Missing Pieces in Hypertriglyceridemia-Induced Pancreatitis"],"prefix":"10.7759","author":[{"given":"Muhammad A","family":"Zaman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karly","family":"Milton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Jilani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.08.045","article-title":"Burden of gastrointestinal, liver, and pancreatic diseases in the United States","volume":"149","author":"Peery AF","year":"2015","unstructured":"Peery AF, Crockett SD, Barritt AS, et al.. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology. 2015, 149:1731-41.e3. 10.1053\/j.gastro.2015.08.045","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0935","article-title":"Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol","volume":"63","author":"Shojaee-Moradie F","year":"2014","unstructured":"Shojaee-Moradie F, Ma Y, Lou S, Hovorka R, Umpleby AM. Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol. Diabetes. 2014, 63:4063-9. 10.2337\/db13-0935","journal-title":"Diabetes"},{"key":"ref3","article-title":"Acute pancreatitis in pregnancy","volume":"61","author":"Chang CC","year":"1998","unstructured":"Chang CC, Hsieh YY, Tsai HD, et al.. Acute pancreatitis in pregnancy. Chin Med J. 1998, 61:85-92.","journal-title":"Chin Med J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221093969","article-title":"Acute pancreatitis secondary to tamoxifen-associated hypertriglyceridemia: a clinical update","volume":"29","author":"Goraya MH","year":"2023","unstructured":"Goraya MH, Abbasi EU, Amin MK, et al.. Acute pancreatitis secondary to tamoxifen-associated hypertriglyceridemia: a clinical update. J Oncol Pharm Pract. 2023, 29:218-25. 10.1177\/10781552221093969","journal-title":"J Oncol Pharm Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-021-01427-1","article-title":"Acute pancreatitis secondary to cocaine use: a case-based systematic literature review","volume":"14","author":"Goraya MH","year":"2021","unstructured":"Goraya MH, Malik A, Inayat F, Ishtiaq R, Zaman MA, Arslan HM, Tarar ZI. Acute pancreatitis secondary to cocaine use: a case-based systematic literature review. Clin J Gastroenterol. 2021, 14:1269-77. 10.1007\/s12328-021-01427-1","journal-title":"Clin J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-017-0517-3","article-title":"Stratified analysis and clinical significance of elevated serum triglyceride levels in early acute pancreatitis: a retrospective study","volume":"16","author":"Wan J","year":"2017","unstructured":"Wan J, He W, Zhu Y, et al.. Stratified analysis and clinical significance of elevated serum triglyceride levels in early acute pancreatitis: a retrospective study. Lipids Health Dis. 2017, 16:124. 10.1186\/s12944-017-0517-3","journal-title":"Lipids Health Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e3283319a1d","article-title":"Severe hypertriglyceridemia and pancreatitis: presentation and management","volume":"20","author":"Ewald N","year":"2009","unstructured":"Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol. 2009, 20:497-504. 10.1097\/MOL.0b013e3283319a1d","journal-title":"Curr Opin Lipidol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-022-01631-z","article-title":"Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia","volume":"21","author":"Paragh G","year":"2022","unstructured":"Paragh G, N\u00e9meth \u00c1, Harangi M, Banach M, F\u00fcl\u00f6p P. Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia. Lipids Health Dis. 2022, 21:21. 10.1186\/s12944-022-01631-z","journal-title":"Lipids Health Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.117476","article-title":"Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS)","volume":"391","author":"Bashir B","year":"2024","unstructured":"Bashir B, Kwok S, Wierzbicki AS, et al.. Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS). Atherosclerosis. 2024, 391:117476. 10.1016\/j.atherosclerosis.2024.117476","journal-title":"Atherosclerosis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \"FCS score\"","volume":"275","author":"Moulin P","year":"2018","unstructured":"Moulin P, Dufour R, Averna M, et al.. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \"FCS score\". Atherosclerosis. 2018, 275:265-72. 10.1016\/j.atherosclerosis.2018.06.814","journal-title":"Atherosclerosis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1480368","article-title":"Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome","volume":"11","author":"Chaudhry R","year":"2018","unstructured":"Chaudhry R, Viljoen A, Wierzbicki AS. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. Expert Rev Clin Pharmacol. 2018, 11:589-98. 10.1080\/17512433.2018.1480368","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum JL","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, et al.. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019, 381:531-42. 10.1056\/NEJMoa1715944","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2022.08.017","article-title":"Efficacy and safety of lomitapide in familial chylomicronaemia syndrome","volume":"359","author":"Cefal\u00f9 AB","year":"2022","unstructured":"Cefal\u00f9 AB, D'Erasmo L, Iannuzzo G, et al.. Efficacy and safety of lomitapide in familial chylomicronaemia syndrome. Atherosclerosis. 2022, 359:13-9. 10.1016\/j.atherosclerosis.2022.08.017","journal-title":"Atherosclerosis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller M","year":"2011","unstructured":"Miller M, Stone NJ, Ballantyne C, et al.. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011, 123:2292-333. 10.1161\/CIR.0b013e3182160726","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-01579-3","article-title":"Metabolic syndrome components and acute pancreatitis: a case-control study in China","volume":"21","author":"Shen Z","year":"2021","unstructured":"Shen Z, Wang X, Zhen Z, Wang Y, Sun P. Metabolic syndrome components and acute pancreatitis: a case-control study in China. BMC Gastroenterol. 2021, 21:17. 10.1186\/s12876-020-01579-3","journal-title":"BMC Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03584-4","article-title":"Acute pancreatitis and metabolic syndrome: genetic correlations and causal associations","volume":"84","author":"Zhu S","year":"2024","unstructured":"Zhu S, Ding Z. Acute pancreatitis and metabolic syndrome: genetic correlations and causal associations. Endocrine. 2024, 84:380-7. 10.1007\/s12020-023-03584-4","journal-title":"Endocrine"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.04.004","article-title":"Metabolic syndrome and acute pancreatitis","volume":"32","author":"Mikolasevic I","year":"2016","unstructured":"Mikolasevic I, Milic S, Orlic L, et al.. Metabolic syndrome and acute pancreatitis. Eur J Intern Med. 2016, 32:79-83. 10.1016\/j.ejim.2016.04.004","journal-title":"Eur J Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2274946","article-title":"Real-world safety of icosapent ethyl: analysis based on spontaneous reports in FAERS database","volume":"23","author":"Cai H","year":"2024","unstructured":"Cai H, Jia B, Fu Z, Chen B, Liu Y, Zhao S. Real-world safety of icosapent ethyl: analysis based on spontaneous reports in FAERS database. Expert Opin Drug Saf. 2024, 23:373-83. 10.1080\/14740338.2023.2274946","journal-title":"Expert Opin Drug Saf"},{"key":"ref19","unstructured":"GLUCOPHAGE\u00ae (metformin hydrochloride) tablets. (2017). Accessed. April 1, 2017: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202057s019lbl.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/302218-beyond-the-obvious-the-missing-pieces-in-hypertriglyceridemia-induced-pancreatitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T17:24:43Z","timestamp":1729617883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/302218-beyond-the-obvious-the-missing-pieces-in-hypertriglyceridemia-induced-pancreatitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.72140","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}